4//SEC Filing
Spear Matthew A. 4
Accession 0001209191-21-028200
CIK 0001661460other
Filed
Apr 22, 8:00 PM ET
Accepted
Apr 23, 8:49 PM ET
Size
12.9 KB
Accession
0001209191-21-028200
Insider Transaction Report
Form 4
Spear Matthew A.
Chief Medical Officer
Transactions
- Sale
Common Stock
2021-04-21$8.44/sh−4,000$33,752→ 11,485 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-23−5,000→ 123,861 totalExercise: $1.32Exp: 2026-06-19→ Common Stock (5,000 underlying) - Exercise/Conversion
Common Stock
2021-04-21$1.32/sh+4,000$5,288→ 15,485 total - Exercise/Conversion
Common Stock
2021-04-23$1.32/sh+5,000$6,610→ 16,485 total - Exercise/Conversion
Stock Option (Right to Buy)
2021-04-21−4,000→ 128,861 totalExercise: $1.32Exp: 2026-06-19→ Common Stock (4,000 underlying)
Footnotes (3)
- [F1]The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on March 22, 2021.
- [F2]The reported price in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $8.32 to $8.65 per share, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
- [F3]The stock option is fully vested and exercisable.
Documents
Issuer
Poseida Therapeutics, Inc.
CIK 0001661460
Entity typeother
Related Parties
1- filerCIK 0001766302
Filing Metadata
- Form type
- 4
- Filed
- Apr 22, 8:00 PM ET
- Accepted
- Apr 23, 8:49 PM ET
- Size
- 12.9 KB